134 related articles for article (PubMed ID: 19519875)
1. A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Pongpudpunth M; Demierre MF; Goldberg LJ
J Cutan Pathol; 2009 Dec; 36(12):1303-7. PubMed ID: 19519875
[TBL] [Abstract][Full Text] [Related]
2. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Graves JE; Jones BF; Lind AC; Heffernan MP
J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
4. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
5. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
6. Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Hepper DM; Wu P; Anadkat MJ
J Am Acad Dermatol; 2011 May; 64(5):996-8. PubMed ID: 21496710
[No Abstract] [Full Text] [Related]
7. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
8. Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
Donovan JC; Ghazarian DM; Shaw JC
Arch Dermatol; 2008 Nov; 144(11):1524-5. PubMed ID: 19015435
[No Abstract] [Full Text] [Related]
9. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Krozely P
Clin J Oncol Nurs; 2004 Apr; 8(2):163-8. PubMed ID: 15108418
[TBL] [Abstract][Full Text] [Related]
10. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
11. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Seiverling EV; Fernanadez EM; Adams D
J Drugs Dermatol; 2006 Apr; 5(4):368-9. PubMed ID: 16673807
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Ong CK; Tan WC; Chan LC; Abdul Razak M
Med J Malaysia; 2012 Apr; 67(2):222-3. PubMed ID: 22822651
[TBL] [Abstract][Full Text] [Related]
14. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Wnorowski AM; de Souza A; Chachoua A; Cohen DE
Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Lee MW; Seo CW; Kim SW; Yang HJ; Lee HW; Choi JH; Moon KC; Koh JK
Acta Derm Venereol; 2004; 84(1):23-6. PubMed ID: 15040473
[TBL] [Abstract][Full Text] [Related]
17. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
Lübbe J; Masouyé I; Dietrich PY
Dermatology; 2008; 216(3):247-9. PubMed ID: 18182820
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib-induced pustular eruption.
Cusano F; Ferrara G; Barletta E; Ingordo V
G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
[TBL] [Abstract][Full Text] [Related]
19. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
LoRusso PM; Herbst RS; Rischin D; Ranson M; Calvert H; Raymond E; Kieback D; Kaye S; Gianni L; Harris A; Bjork T; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Feyereislova A; Heyes A; Averbuch SD; Ochs J; Baselga J
Clin Cancer Res; 2003 Jun; 9(6):2040-8. PubMed ID: 12796366
[TBL] [Abstract][Full Text] [Related]
20. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
